Scientists at The University of Texas at Austin have pulled off their clearest look yet at the Andes hantavirus, mapping the virus’s surface entry complex at near-atomic detail. That intricate blueprint shows how the pathogen latches onto and fuses with human cells and underpins a structure-based vaccine candidate that, in lab tests, pushed mice to generate neutralizing antibodies. The work closes a long-standing gap in hantavirus research and could help accelerate targeted vaccines and antibody therapies.
UT Austin Built The Blueprint
As reported by UT Austin News, a team led by Jason McLellan used structural biology to both capture a high-resolution model of the Andes hantavirus entry machinery and turn that insight into a vaccine candidate. “Now that we have a better blueprint of what the virus looks like, we can design effective vaccines and antibody therapies for hantaviruses,” McLellan said in the university’s release. The coverage identifies Luqiang Guo as first author and credits other lab members and contributors.
Why Hantaviruses Have Public-Health Officials On Edge
Hantaviruses are rodent-borne pathogens that can trigger hantavirus pulmonary syndrome, a severe respiratory disease with a high death rate and no approved antiviral drugs or vaccines. According to the CDC, roughly 38 percent of people who develop respiratory symptoms from HPS die, a sobering figure that underlines why researchers keep calling for new countermeasures. Outbreaks tend to be sporadic but severe, which is why public-health experts treat preemptive vaccine design as a high priority rather than a nice-to-have.
How The Team Saw The Virus Up Close
The researchers turned to cryo-electron microscopy on engineered virus-like particles, then got picky about their images. By selecting Gn–Gc tetramers that were oriented sidewise to the electron beam, they pushed the structure to unprecedented detail. The peer-reviewed paper describes a reconstruction at roughly 2.35 angstrom resolution and a complete in-situ model that fixes earlier, lower-resolution fits. Those maps let scientists pinpoint intersubunit interfaces that make logical bullseyes for vaccines and monoclonal antibodies, according to the article in Cell.
Vaccine Candidate Sparked Neutralizing Antibodies In Mice
Using the new structural template, the team designed a vaccine candidate and moved it into mouse studies, where it triggered neutralizing antibody responses the authors describe as encouraging preclinical evidence. Reporters note that the group used a replicon RNA/LION delivery platform to express Andes hantavirus glycoprotein constructs and that several vaccine formulations induced robust binding and neutralizing responses in the murine experiments. Animal data are still an early rung on the ladder, but the results back the idea that high-resolution structures can steer antigen design, per reporting by Scienmag.
Funding, Partners And The ReVAMPP Push
According to NIH materials, the work received support from the National Institutes of Health, the Welch Foundation and the Cancer Prevention and Research Institute of Texas and was carried out within the NIH’s broader pandemic-preparedness efforts. The NIH’s ReVAMPP program specifically names hantaviruses as high-priority targets for prepositioned vaccine and antibody research. The study’s author list and university coverage also point to collaborators at Texas A&M, UT Southwestern and industry partner HDT Bio in Seattle, reflecting a cross-institutional effort, as reported by UT Austin News and NIH documents.
Investigators say the new maps allowed them to design stabilizing mutations that lock the Gn–Gc tetramer in its vulnerable pre-fusion state, and they plan to lean on computational tools, including artificial-intelligence-driven protein design, to select those changes and refine vaccine antigens. The team notes that further immunogenicity and stability testing will be needed before anyone talks seriously about human trials, so the road ahead is still long. Early coverage suggests the ambition is a plug-and-play design strategy that shortens the path from high-resolution structure to a vaccine or antibody countermeasure, according to Phys.org…